{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:07:50Z","timestamp":1791864470727,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioid agonist therapy (OAT) uptake has been associated with multiple positive health outcomes among people who inject drugs (PWID). This study evaluated the pattern of OAT uptake among PWID in two consecutive national bio-behavioral surveillance surveys (2010 and 2014) in Iran.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data were obtained from two national bio-behavioral surveillance surveys (\n                      <jats:italic>N<\/jats:italic>\n                      <jats:sub>2010<\/jats:sub>\n                      = 1783 and\n                      <jats:italic>N<\/jats:italic>\n                      <jats:sub>2014<\/jats:sub>\n                      = 2166) implemented using convenience sampling at the harm reduction facilities and street venues in 10 geographically diverse urban centers across Iran. Multivariable logistic regression models were built to determine the correlates of OAT uptake for the 2014 survey, and adjusted odds ratios (AORs)\u00a0along with 95% confidence intervals (CI) were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The prevalence of OAT uptake decreased from 49.2% in 2010 to 45.8% in 2014 (\n                      <jats:italic>P<\/jats:italic>\n                      value = 0.033). OAT uptake varied across the studied cities ranging from 0.0 to 69.3% in the 2010 survey and 3.2 to 75.5% in the 2014 survey. Ever being married (AOR = 1.40; 95% CI 1.12, 1.75), having a history of incarceration (AOR = 1.56; 95% CI 1.16, 2.09), and human immunodeficiency virus (HIV) sero-positivity (AOR = 1.63; 95% CI 1.08, 2.50) were associated with OAT uptake. Conversely, PWID who reported using only non-opioid drugs (AOR = 0.43; 95% CI 0.26, 0.71) and those who reported concurrent use of opioid and non-opioid drugs (AOR = 0.66; 95% CI 0.51, 0.86) were less likely to uptake OAT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although OAT uptake among PWID in Iran is above the 40% threshold defined by the World Health Organization, there remain significant disparities across urban settings in Iran. Importantly, the OAT services appear to be serving high-risk PWID including those living with HIV and those with a history of incarceration. Evaluating service integration including mental health, HIV and hepatitis C virus care, and other harm reduction services may support the optimization of health outcomes associated with\u00a0OAT across Iran.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-020-00392-1","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T05:07:57Z","timestamp":1595394477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6975","authenticated-orcid":false,"given":"Mehran","family":"Nakhaeizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Abdolahinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-7618","authenticated-orcid":false,"given":"Hamid","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-3220","authenticated-orcid":false,"given":"Ali","family":"Mirzazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4628-4849","authenticated-orcid":false,"given":"Ali Akbar","family":"Haghdoost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3810-752X","authenticated-orcid":false,"given":"Mostafa","family":"Shokoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5482-2419","authenticated-orcid":false,"given":"Stefan","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5631-4469","authenticated-orcid":false,"given":"Mohammad","family":"Karamouzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-319X","authenticated-orcid":false,"given":"Armita","family":"Shahesmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"392_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.drugpo.2016.01.013","volume":"31","author":"A Nikfarjam","year":"2016","unstructured":"Nikfarjam A, Shokoohi M, Shahesmaeili A, Haghdoost AA, Baneshi MR, Haji-Maghsoudi S, et al. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran. Int J Drug Policy [Internet]. Elsevier. 2016;31:147\u201352 https:\/\/doi.org\/10.1016\/j.drugpo.2016.01.013.","journal-title":"Elsevier"},{"key":"392_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijid.2015.09.022","volume":"40","author":"M Malekinejad","year":"2015","unstructured":"Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movaghar A, Amin-Esmaeili M, Noroozi A. High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001\u20132012). Int J Infect Dis [Internet]. Elsevier. 2015;40:116\u201330 https:\/\/doi.org\/10.1016\/j.ijid.2015.09.022.","journal-title":"Elsevier"},{"key":"392_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.drugpo.2011.09.002","volume":"23","author":"A Rahimi-Movaghar","year":"2012","unstructured":"Rahimi-Movaghar A, Amin-Esmaeili M, Haghdoost AA, Sadeghirad B, Mohraz M. HIV prevalence amongst injecting drug users in Iran: a systematic review of studies conducted during the decade 1998\u20132007. Int J Drug Policy [Internet]. Elsevier. 2012;23:271\u20138 https:\/\/doi.org\/10.1016\/j.drugpo.2011.09.002.","journal-title":"Elsevier"},{"key":"392_CR4","doi-asserted-by":"crossref","unstructured":"Khajehkazemi R, Osooli M, Sajadi L, Karamouzian M, Sedaghat A, Fahimfar N, et al. HIV prevalence and risk behaviours among people who inject drugs in Iran: the 2010 National Surveillance Survey. Sex Transm Infect. BMJ Publishing Group Ltd; 2013;89:iii29-iii32. doi:10.1136\/sextrans-2013-051204.","DOI":"10.1136\/sextrans-2013-051204"},{"key":"392_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10461-018-2144-z","volume":"22","author":"A Shahesmaeili","year":"2018","unstructured":"Shahesmaeili A, Mirzazadeh A, McFarland W, Sharifi H, Haghdoost AA, Soori H. Syringe sharing in drug injecting dyads: a cross-classified multilevel analysis of social networks. AIDS Behav. Springer. 2018;22:10\u20138. https:\/\/doi.org\/10.1007\/s10461-018-2144-z.","journal-title":"AIDS Behav. Springer"},{"key":"392_CR6","doi-asserted-by":"publisher","unstructured":"Ekhtiari H, Noroozi A, Farhoudian A, Radfar SR, Hajebi A, Sefatian S, et al. The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity? Addiction. Wiley Online Library. 2019. https:\/\/doi.org\/10.1111\/add.14905.","DOI":"10.1111\/add.14905"},{"key":"392_CR7","unstructured":"Farhoudi B, Kamali K, Gouya MM, Sedaghat A. Haghdoost A. Islamic Republic of Iran Progress Report On Monitoring of the United Nations General. 2012:1\u201384."},{"key":"392_CR8","doi-asserted-by":"publisher","unstructured":"Khazaee-Pool M, Moeeni M, Ponnet K, Fallahi A, Jahangiri L, Pashaei T. Perceived barriers to methadone maintenance treatment among Iranian opioid users. Int J Equity Health. International Journal for Equity in Health; 2018;17:1\u201310. doi:https:\/\/doi.org\/10.1186\/s12939-018-0787-z.","DOI":"10.1186\/s12939-018-0787-z"},{"key":"392_CR9","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.jfda.2013.09.035","volume":"21","author":"DCD Jarlais","year":"2013","unstructured":"Jarlais DCD, Des Jarlais DC. Systematic review research on needle\/syringe programs and opiate substitution programs in low-and middle-income countries. J food drug Anal [Internet]. Elsevier. 2013;21:S59\u201361 Available from: https:\/\/doi.org\/10.1016\/j.jfda.2013.09.035.","journal-title":"Elsevier"},{"key":"392_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.drugpo.2011.09.001","volume":"23","author":"M Malekinejad","year":"2012","unstructured":"Malekinejad M, Vazirian M. Transition to injection amongst opioid users in Iran: implications for harm reduction. Int J Drug Policy. Elsevier. 2012;23:333\u20137. https:\/\/doi.org\/10.1016\/j.drugpo.2011.09.001.","journal-title":"Int J Drug Policy. Elsevier"},{"key":"392_CR11","doi-asserted-by":"publisher","unstructured":"Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. Springer; 2006;3:12. doi:https:\/\/doi.org\/10.1186\/1477-7517-3-12.","DOI":"10.1186\/1477-7517-3-12"},{"key":"392_CR12","doi-asserted-by":"publisher","unstructured":"Vickerman P, Page K, Maher L, Hickman M. Opiate substitution treatment and HCV prevention: building an evidence base? Addiction. NIH Public Access; 2014;109:2060. doi: https:\/\/doi.org\/10.1111\/add.12750.","DOI":"10.1111\/add.12750"},{"key":"392_CR13","unstructured":"Pourkhajoei S, Barouni M, Noroozi A, Hajebi A, Amini S, Karamouzian M, et al. Cost-effectiveness of methadone maintenance treatment centers in prevention of human immunodeficiency virus infection. Addict Heal. Kerman University of Medical Sciences; 2017;9:81."},{"key":"392_CR14","doi-asserted-by":"crossref","unstructured":"Kermode M, Crofts N, Kumar MS, Dorabjee J. Opioid substitution therapy in resource-poor settings [Internet]: SciELO Public Health; 2011. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5742414\/.","DOI":"10.2471\/BLT.11.086850"},{"key":"392_CR15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s10461-018-2345-5","volume":"23","author":"A Esmaeili","year":"2019","unstructured":"Esmaeili A, Shokoohi M, Danesh A, Sharifi H, Karamouzian M, Haghdoost A, et al. Dual unsafe injection and sexual behaviors for HIV infection among people who inject drugs in Iran. AIDS Behav. Springer. 2019;23:1594\u2013603. https:\/\/doi.org\/10.1007\/s10461-018-2345-5.","journal-title":"AIDS Behav. Springer"},{"key":"392_CR16","unstructured":"World Health Organization (WHO) - UNODOC - UNAIDS. WHO, UNODC, UNAIDS Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for IDI. 2012; Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/77969\/9789241504379_eng.pdf;jsessionid = E6AEB02E6241765FC44B9E02F7E8B7D9?sequence = 1."},{"key":"392_CR17","unstructured":"Sepehrdoust H. Health care analysis and regional disparities in different provinces of Iran. Iran Econ Rev. University of Tehran, Faculty of Economics; 2009;14:113\u201334."},{"key":"392_CR18","unstructured":"Roshanfekr P, Farnia M, Dejman M. The effectiveness of harm reduction programs in seven prisons of Iran. Iran J Public Health [Internet]. Tehran University of Medical Sciences; 2013;42:1430. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4441940\/."},{"key":"392_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ajp.2015.06.002","volume":"16","author":"Z Alam-mehrjerdi","year":"2015","unstructured":"Alam-mehrjerdi Z, Abdollahi M, Higgs P, Dolan K. Drug use treatment and harm reduction programs in Iran: a unique model of health in the most populated Persian Gulf country. Asian J Psychiatr. Elsevier. 2015;16:78\u201383. https:\/\/doi.org\/10.1016\/j.ajp.2015.06.002.","journal-title":"Asian J Psychiatr. Elsevier"},{"key":"392_CR20","doi-asserted-by":"publisher","unstructured":"Danesh A, Noroozi A. Concurrent amphetamine and methamphetamine use among clients of opioid maintenance treatment programs in Golestan, Iran. Iran J Psychiatry Behav Sci. Kowsar; 2019;13:e74234. doi: https:\/\/doi.org\/10.5812\/ijpbs.74234.","DOI":"10.5812\/ijpbs.74234"},{"key":"392_CR21","doi-asserted-by":"publisher","unstructured":"Radfar SR, Cousins SJ, Shariatirad S, Noroozi A, Rawson RA. Methamphetamine use among patients undergoing methadone maintenance treatment in Iran; a threat for harm reduction and treatment strategies: A qualitative study. Int J High Risk Behav Addict. Kowsar; 2016;5. doi: https:\/\/doi.org\/10.5812\/ijhrba.30327.","DOI":"10.5812\/ijhrba.30327"},{"key":"392_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5812\/ijhrba.30327","volume":"21","author":"S Zamani","year":"2010","unstructured":"Zamani S, Farnia M, Tavakoli S, Gholizadeh M, Nazari M, Seddighi A-A, et al. A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran. Iran. Int J Drug Policy. Elsevier. 2010;21:167\u201372. https:\/\/doi.org\/10.5812\/ijhrba.30327.","journal-title":"Iran. Int J Drug Policy. Elsevier"},{"key":"392_CR23","doi-asserted-by":"publisher","unstructured":"Radfar SR, Mohsenifar S, Noroozi A. Integration of methamphetamine harm reduction into opioid harm reduction services in Iran: preliminary results of a pilot study. Iran J Psychiatry Behav Sci. Kowsar; 2017;11:e7730. doi:https:\/\/doi.org\/10.5812\/ijpbs.7730.","DOI":"10.5812\/ijpbs.7730"},{"key":"392_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5055\/jom.2006.0006","volume":"2","author":"C Callon","year":"2006","unstructured":"Callon C, Wood E, Marsh D, Li K, Montaner J, Kerr T. Barriers and facilitators to methadone maintenance therapy use among illicit opiate injection drug users in Vancouver. J Opioid Manag [Internet]. 2006;2:35\u201341 Available from: https:\/\/www.researchgate.net\/profile\/David_Marsh3\/publication\/6487367_Barriers_and_facilitators_to_methadone_maintenance_therapy_use_among_illicit_opiate_injection_drug_users_in_Vancouver\/links\/56786f9008aebcdda0ebd8bf\/Barriers-and-facilitators-to-methado.","journal-title":"J Opioid Manag [Internet]."},{"key":"392_CR25","doi-asserted-by":"crossref","unstructured":"Haldane V, Cervero-Liceras F, Chuah FLH, Ong SE, Murphy G, Sigfrid L, et al. Integrating HIV and substance use services: a systematic review. J Int AIDS Soc. Wiley Online Library; 2017;20:21585. doi: 10.7448\/IAS.20.1.21585.","DOI":"10.7448\/IAS.20.1.21585"},{"key":"392_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/cid\/ciw416","volume":"63","author":"AJ Low","year":"2016","unstructured":"Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. Oxford University Press. 2016;63:1094\u2013104. https:\/\/doi.org\/10.1093\/cid\/ciw416.","journal-title":"Clin Infect Dis. Oxford University Press"},{"key":"392_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annepidem.2019.04.011","volume":"35","author":"M Karamouzian","year":"2019","unstructured":"Karamouzian M, Shokoohi M, Kaplan RL, Noroozi A, Sharifi H, Baral SD, et al. Characterizing the relationship between incarceration and structural risks among female sex workers in Iran: findings of a nationwide biobehavioral surveillance survey. Ann Epidemiol. Elsevier. 2019;35:29\u201334. https:\/\/doi.org\/10.1016\/j.annepidem.2019.04.011.","journal-title":"Ann Epidemiol. Elsevier"},{"key":"392_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10935-019-00574-z","volume":"41","author":"G Moradi","year":"2020","unstructured":"Moradi G, Darvishi S, Asaadi L, Zavareh FA, Gouya M-M, Tashakorian M, et al. Patterns of drug use and related factors among prisoners in Iran: results from the national survey in 2015. J Prim Prev. Springer. 2020;41:1\u201310. https:\/\/doi.org\/10.1007\/s10935-019-00574-z.","journal-title":"J Prim Prev. Springer"},{"key":"392_CR29","first-page":"2","volume":"119","author":"G Nikpour","year":"2019","unstructured":"Nikpour G. Drugs and drug policy in the Islamic Republic of Iran. Middle East Briefs [Internet]. 2019;119:2\u20137 Available from: www.academia.edu\/download\/56979517\/CrownCenterMiddleEastBriefPDF.pdf.","journal-title":"Middle East Briefs [Internet]."},{"key":"392_CR30","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/add.13779","volume":"112","author":"J Marsden","year":"2017","unstructured":"Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction. Wiley Online Library. 2017;112:1408\u201318. https:\/\/doi.org\/10.1111\/add.13779.","journal-title":"Addiction. Wiley Online Library"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-020-00392-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T19:45:49Z","timestamp":1626896749000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00392-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1186\/s12954-020-00392-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-24098\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-24098\/v2","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"20 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Research Ethics Committee (REB) at Kerman University of Medical Sciences (Ethics code No: IR.KMU.REC.597 and K\/93\/208). Verbal informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree with the content of this manuscript and have given consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}